When should nivolumab (Opdivo) be used in patients with classical Hodgkin lymphoma who have relapsed or refractory disease after prior systemic therapy?

When to Use Nivolumab in Classical Hodgkin Lymphoma

Nivolumab should be used in adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after both autologous hematopoietic stem cell transplantation (HSCT) AND brentuximab vedotin, or after 3 or more lines of systemic therapy that includes autologous HSCT. 1

FDA-Approved Indications

The FDA label is explicit about when nivolumab is indicated 1:

• After HSCT failure AND brentuximab vedotin failure, OR
• After ≥3 lines of systemic therapy including HSCT

This is an accelerated approval based on overall response rate, meaning continued approval depends on confirmatory trial results demonstrating clinical benefit.

Guideline-Based Treatment Algorithm

Sequential Treatment Pathway

First-line relapse/refractory approach:

1. Initial salvage: Use platinum-based chemotherapy (ICE, DHAP, IGEV) or brentuximab vedotin to achieve cytoreduction 2, 3
2. Consolidation: Proceed to high-dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) 3
3. Post-ASCT consolidation: Consider brentuximab vedotin for patients with poor-risk factors 3

When ASCT fails:

• Next step: Single-agent brentuximab vedotin 3
• After brentuximab failure: Nivolumab or pembrolizumab 3

Critical Decision Points

Nivolumab becomes the treatment of choice when:

• Patient has progressed through ASCT AND brentuximab vedotin
• Patient has received ≥3 prior systemic therapies including ASCT
• Patient is not a candidate for allogeneic stem cell transplantation or has declined it

Clinical Efficacy Data

The CheckMate 205 trial with extended 18-month follow-up demonstrated 4:

• Objective response rate: 69% (95% CI: 63-75%)
• Median duration of response: 16.6 months
• Median progression-free survival: 14.7 months
• Responses were consistent across all cohorts regardless of brentuximab vedotin timing

Real-world data confirms these findings with objective response rates of 46-64% 5, 6.

Dosing and Administration

Standard regimen: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity 1, 4

Key consideration: Treatment can continue beyond conventional disease progression if the patient is clinically stable—61% of patients treated past progression had stable or further reduced tumor burden 4.

Safety Profile and Management

Common adverse events (≥20%): 7

• Fatigue
• Upper respiratory tract infection
• Cough, pyrexia, diarrhea
• Elevated transaminases
• Cytopenias

Immune-mediated toxicities requiring monitoring:

• Hypothyroidism/thyroiditis (>10%) - monitor thyroid function regularly
• Pneumonitis (1-5%) - can occur late (≥17 months after initiation) 8
• Hepatitis, colitis, rash (1-5% each)
• Infusion reactions (>10%)

Critical safety warning: There is increased risk of severe/hyperacute graft-versus-host disease and transplant-related mortality if allogeneic HSCT is performed after nivolumab 7. This requires careful risk-benefit evaluation.

Special Considerations

Bridge to transplantation: Nivolumab can serve as a bridge to allogeneic stem cell transplantation in selected young, chemosensitive patients in good general condition 3, 6. However, the safety profile requires careful monitoring, as 5 of 11 patients undergoing allogeneic HSCT after nivolumab in one series achieved complete response and remained alive 6.

When nivolumab is NOT appropriate:

• As first-line salvage therapy before attempting HSCT
• Before brentuximab vedotin has been tried (unless part of a clinical trial)
• In patients who have not yet received HSCT and are transplant-eligible

Alternative if nivolumab fails: Consider allogeneic stem cell transplantation in carefully selected patients, or gemcitabine-based palliative chemotherapy with/without regional radiotherapy 3.

Common Pitfalls to Avoid

1. Do not use nivolumab too early - it is specifically indicated after HSCT and brentuximab vedotin failure, not as initial salvage
2. Monitor for late pulmonary toxicity - pneumonitis can occur >17 months after starting treatment 8
3. Exercise extreme caution with subsequent allogeneic HSCT - increased risk of severe complications 7
4. Do not automatically stop at progression - consider continuing if patient is clinically stable, as 61% had further benefit 4